PBYI - Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data
- Puma Biotechnology continues to report encouraging clinical data for its flagship product, NERLYNX. Unfortunately, the commercial numbers continue to remain in purgatory.
- I take a look at the company's recent earnings report to extract some key commercial metrics and trends that have developed over 2020.
- I review some of the recent clinical data and point out some key takeaways for investors.
- I discuss my plans for my undersized PBYI position.
For further details see:
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data